c-IAP1 (F7C3U) Rabbit mAb #96099
- WB
- IP
- F
Supporting Data
| REACTIVITY | H M |
| SENSITIVITY | Endogenous |
| MW (kDa) | 62 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
| Flow Cytometry (Fixed/Permeabilized) | 1:400 - 1:1600 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
c-IAP1 (gene name: BIRC2), which is structurally and functionally closely related to c-IAP2 (gene name: BIRC3), also contains a RING domain that confers E3 ubiquitin ligase activity (7). c-IAP1 is recruited to the TNF receptor complex upon ligand binding and functions as a positive regulator of the canonical NF-κB signaling pathway, leading to autoubiquitination as well as ubiquitination of other signaling targets, including RIP1 and TRAF family members (8-11). c-IAP is frequently overexpressed in many cancers, contributing to tumorigenesis by inhibiting apoptosis (12,13). IAP inhibitors, like Smac mimetics, can result in c-IAP1 degradation and have been pursued as therapeutic opportunities (14).
- Deveraux, Q.L. and Reed, J.C. (1999) Genes Dev 13, 239-52.
- Deveraux, Q.L. et al. (1998) EMBO J 17, 2215-23.
- Altieri, D.C. et al. (1999) Lab Invest 79, 1327-33.
- Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803.
- Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46.
- Deveraux, Q.L. et al. (1997) Nature 388, 300-4.
- Rothe, M. et al. (1995) Cell 83, 1243-52.
- Yang, Y. et al. (2000) Science 288, 874-7.
- Varfolomeev, E. et al. (2008) J Biol Chem 283, 24295-9.
- Li, X. et al. (2002) Nature 416, 345-7.
- Mao, A.P. et al. (2010) J Biol Chem 285, 9470-9476.
- LaCasse, E.C. et al. (1998) Oncogene 17, 3247-59.
- Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803.
- Feltham, R. et al. (2011) J Biol Chem 286, 17015-28.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.